2024-10-17 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. Its cumulative return of 36.95% lags significantly behind the S&P 500 (VOO) which has returned 135.94%. This results in a relative divergence of -98.99, meaning JNJ is currently performing much worse than the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $164.10
* **5-day Moving Average:** $161.66
* **20-day Moving Average:** $161.96
* **60-day Moving Average:** $162.03

JNJ's current price is slightly above its 5-day, 20-day, and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 66.79 -  JNJ is currently in the overbought territory, suggesting that the stock price may be due for a correction. 
* **PPO:** 0.08 - This positive value indicates that JNJ's price momentum is slightly above its 12-period average. 
* **Delta_Previous_Relative_Divergence:** -7.68 - The negative value indicates a short-term downward trend.
* **Expected Return:** 0.0% - The expected return for JNJ over the next five years is currently estimated at 0%, implying a potential underperformance compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ's recent earnings have been mixed, with some quarters showing growth while others have experienced decline. The most recent earnings report for the quarter ending July 25th, 2024, showed an EPS of $1.95 and revenue of $22.45 billion. While revenue exceeded expectations, EPS fell short of analyst estimates. 

**5. News and Recent Issues:**

**Recent Market Outlook:** JNJ has faced challenges in recent years due to lawsuits and regulatory scrutiny related to its talcum powder products. However, the company is actively addressing these concerns, and its strong pharmaceutical and medical device segments continue to drive growth. 

**Analyst Opinions:** Analysts generally have a mixed outlook on JNJ, with some predicting a potential rebound driven by its strong product portfolio and consistent dividend payouts. However, concerns remain about the ongoing lawsuits and the impact on future earnings.

**Performance Highlights:**  JNJ's consistent dividend payments and history of share buybacks are attractive features for long-term investors. The company's strong position in the healthcare industry provides a degree of stability even during market downturns.

**6. Summary:**

JNJ currently underperforms the S&P 500, with its price showing a slight upward trend. Its technical indicators are mixed, suggesting potential for both upward and downward movement. Although the company's earnings have been mixed, its strong fundamentals and robust product portfolio continue to attract investors. 

**7. Conclusion:**

While JNJ has faced recent challenges, its long-term prospects remain positive. The company's commitment to innovation, strong cash flow, and commitment to dividend payouts make it a potentially attractive investment for long-term investors. However, investors should monitor the ongoing legal issues and their potential impact on the company's future performance.

**Disclaimer:** This report is for informational purposes only and does not constitute investment advice. Always consult with a financial professional before making any investment decisions.